COLINZ
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
This data is currently unavailable for this company.
Events:
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Colinz Laboratories do?
Colinz Laboratories Ltd manufactures a wide range of pharmaceutical formulations, including tablets, capsules, creams, and veterinary and nutraceutical products. They also provide turnkey projects for pharma formulation plants and technical know-how transfer.
Who are the competitors of Colinz Laboratories?
Colinz Laboratories major competitors are Link Pharma Chem, Beryl Drugs, Emmessar Biotech&Nut, Parmax Pharma, Shamrock Indl. Co, Unjha Formulations, Ortin Global. Market Cap of Colinz Laboratories is ₹11 Crs. While the median market cap of its peers are ₹11 Crs.
Is Colinz Laboratories financially stable compared to its competitors?
Colinz Laboratories seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Colinz Laboratories pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Colinz Laboratories latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Colinz Laboratories allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Colinz Laboratories balance sheet?
Balance sheet of Colinz Laboratories is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Colinz Laboratories improving?
Yes, profit is increasing. The profit of Colinz Laboratories is ₹0.5 Crs for Mar 2025, ₹0.49 Crs for Mar 2024 and ₹0.46 Crs for Mar 2023
Is the debt of Colinz Laboratories increasing or decreasing?
Yes, The net debt of Colinz Laboratories is increasing. Latest net debt of Colinz Laboratories is -₹6.76 Crs as of Sep-25. This is greater than Mar-25 when it was -₹10.45 Crs.
Is Colinz Laboratories stock expensive?
Colinz Laboratories is not expensive. Latest PE of Colinz Laboratories is 22.37, while 3 year average PE is 27.39. Also latest EV/EBITDA of Colinz Laboratories is 10.22 while 3yr average is 11.05.
Has the share price of Colinz Laboratories grown faster than its competition?
Colinz Laboratories has given better returns compared to its competitors. Colinz Laboratories has grown at ~11.99% over the last 4yrs while peers have grown at a median rate of 1.37%
Is the promoter bullish about Colinz Laboratories?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Colinz Laboratories is 66.0% and last quarter promoter holding is 66.0%.
Are mutual funds buying/selling Colinz Laboratories?
There is Insufficient data to gauge this.
